The 4.5% Return This Week Takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Five-year Gains to 127%
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
KalVista Wins New Buy at BofA on Potential of Lead Candidate
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Institutional Investors Lost 5.5% Last Week but Have Benefitted From Longer-term Gains
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator
Sean Parker : thanks buddy
Ken Sir : Thank you!
Lnova : Yes secure profits ffs I learned my lesson last week with Tesla
Jenna Ragan : Thank you kindly
Monster madness : Your awesome Jag, thank you
View more comments...